Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fabio Mascella

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Medicina (Kaunas, Lithuania)|January 8, 2025
Effectiveness and Predictors of Long-Term Treatment Response to Tofacitinib in Rheumatoid Arthritis Cohort: General Analysis and Focus on High-Cardiovascular-Risk Subgroup-A Multicenter StudyMarta Priora, Andrea Becciolini, Eleonora Celletti, et al.
Journal of Clinical Medicine|July 13, 2024
Influence of Safety Warnings on the Prescribing Attitude of JAK Inhibitors for Rheumatoid Arthritis in ItalyMarino Paroli, Andrea Becciolini, Alberto Lo Gullo, et al.
Therapeutic Advances in Musculoskeletal Disease|May 11, 2026
Drug retention of TNF versus IL-23 inhibitors in psoriatic arthritis: a multicenter real-life cohort studySimone Parisi, Andrea Becciolini, Bernardo D'Onofrio, et al.
Rheumatology and Therapy|December 4, 2025
Filgotinib Effectiveness in Rheumatoid Arthritis: Observational Analysis of a Large Multicenter CohortEleonora Celletti, Myriam Di Penta, Alarico Ariani, et al.
Journal of Psoriasis and Psoriatic Arthritis|June 12, 2026
Ixekizumab Treatment Persistence in Psoriatic Arthritis: Response to Joaquin et alCamilla Mazzanti, Marino Paroli, Gianluca Santoboni, et al.
Journal of Psoriasis and Psoriatic Arthritis|May 16, 2025
Ixekizumab Retention Rate and Predictors of Treatment Persistence in Psoriatic Arthritis: Results of an Italian Multicenter StudyCamilla Mazzanti, Marino Paroli, Gianluca Santoboni, et al.
Mediterranean Journal of Rheumatology|June 29, 2026
Real-World Effectiveness of Baricitinib in Rheumatoid Arthritis: Significant Reduction of Disease Activity Independent of Age in a Multicentre Retrospective Cohort StudyDaniele Lini, Matteo Colina, Romina Andracco, et al.
Scientific Reports|June 2, 2026
Six months predictors of DAPSA Remission With Guselkumab in Psoriatic Arthritis in a Multicenter Real-World StudyAlessandro Conforti, Alarico Ariani, Martina Gentile, et al.
Rheumatology Advances in Practice|September 22, 2025
Guselkumab effectiveness in real-world settings: observations from an Italian multicentre studyAndrea Becciolini, Antonio Marchesoni, Simone Parisi, et al.
Rheumatology and Therapy|March 14, 2026
Does Prior Exposure Affect Retention? A Real-World, Multicentre Assessment of IL-17 Inhibitor Cycling in Psoriatic ArthritisValentino Paci, Alarico Ariani, Eleonora Celletti, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Medicina (Kaunas, Lithuania)|January 8, 2025
Effectiveness and Predictors of Long-Term Treatment Response to Tofacitinib in Rheumatoid Arthritis Cohort: General Analysis and Focus on High-Cardiovascular-Risk Subgroup-A Multicenter StudyMarta Priora, Andrea Becciolini, Eleonora Celletti, et al.
Journal of Clinical Medicine|July 13, 2024
Influence of Safety Warnings on the Prescribing Attitude of JAK Inhibitors for Rheumatoid Arthritis in ItalyMarino Paroli, Andrea Becciolini, Alberto Lo Gullo, et al.
Therapeutic Advances in Musculoskeletal Disease|May 11, 2026
Drug retention of TNF versus IL-23 inhibitors in psoriatic arthritis: a multicenter real-life cohort studySimone Parisi, Andrea Becciolini, Bernardo D'Onofrio, et al.
Rheumatology and Therapy|December 4, 2025
Filgotinib Effectiveness in Rheumatoid Arthritis: Observational Analysis of a Large Multicenter CohortEleonora Celletti, Myriam Di Penta, Alarico Ariani, et al.
Journal of Psoriasis and Psoriatic Arthritis|June 12, 2026
Ixekizumab Treatment Persistence in Psoriatic Arthritis: Response to Joaquin et alCamilla Mazzanti, Marino Paroli, Gianluca Santoboni, et al.
Journal of Psoriasis and Psoriatic Arthritis|May 16, 2025
Ixekizumab Retention Rate and Predictors of Treatment Persistence in Psoriatic Arthritis: Results of an Italian Multicenter StudyCamilla Mazzanti, Marino Paroli, Gianluca Santoboni, et al.
Mediterranean Journal of Rheumatology|June 29, 2026
Real-World Effectiveness of Baricitinib in Rheumatoid Arthritis: Significant Reduction of Disease Activity Independent of Age in a Multicentre Retrospective Cohort StudyDaniele Lini, Matteo Colina, Romina Andracco, et al.
Scientific Reports|June 2, 2026
Six months predictors of DAPSA Remission With Guselkumab in Psoriatic Arthritis in a Multicenter Real-World StudyAlessandro Conforti, Alarico Ariani, Martina Gentile, et al.
Rheumatology Advances in Practice|September 22, 2025
Guselkumab effectiveness in real-world settings: observations from an Italian multicentre studyAndrea Becciolini, Antonio Marchesoni, Simone Parisi, et al.
Rheumatology and Therapy|March 14, 2026
Does Prior Exposure Affect Retention? A Real-World, Multicentre Assessment of IL-17 Inhibitor Cycling in Psoriatic ArthritisValentino Paci, Alarico Ariani, Eleonora Celletti, et al.
Pageof 2